{"id":"spikevax-bivalent-original-omicron-ba-1","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain"},{"rate":"30-50","effect":"Fatigue"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Myalgia"},{"rate":"10-20","effect":"Fever"},{"rate":"10-20","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Spikevax bivalent Original/Omicron BA.1 is a messenger RNA vaccine that instructs cells to produce spike proteins from two different SARS-CoV-2 strains simultaneously. This dual-antigen approach aims to broaden immune coverage and improve protection against both ancestral and Omicron BA.1 variant infections. The vaccine triggers both humoral and cellular immune responses through the lipid nanoparticle delivery system.","oneSentence":"This bivalent mRNA vaccine encodes spike proteins from both the original SARS-CoV-2 strain and the Omicron BA.1 variant to elicit immune responses against multiple viral variants.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:52.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults (booster dose)"}]},"trialDetails":[{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152},{"nctId":"NCT05236491","phase":"PHASE2, PHASE3","title":"COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases","status":"UNKNOWN","sponsor":"Paul R Fortin","startDate":"2022-03-09","conditions":"Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus","enrollment":287}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Spikevax bivalent Original/Omicron BA.1","genericName":"Spikevax bivalent Original/Omicron BA.1","companyName":"Jules Bordet Institute","companyId":"jules-bordet-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"This bivalent mRNA vaccine encodes spike proteins from both the original SARS-CoV-2 strain and the Omicron BA.1 variant to elicit immune responses against multiple viral variants. Used for COVID-19 prevention in adults (booster dose).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}